Wednesday, October 12, 2016

Anti-PD-1 Drugs Vie for Urothelial Cancer Indication (CME/CE)

(MedPage Today) -- Pembrolizumab active in cisplatin-ineligible disease, nivolumab in recurrence
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)